Shares of drug maker Lupiun fell over 1 per cent on the Bombay Stock Exchange, hitting 52-week low, after media report suggested that US FDA has issued Form 483 with three observations to company's Goa plant.
Reacting to the news, shares of the company declined as much as 1.31 per cent to hit 52-week low of Rs 1319.60 apiece on the Bombay Stock Exchange. The scrip was currently trading at Rs 1323.05 against previous close price of Rs 1337.25.
In a similar fashion, stocks of company were trading 0.94 per cent lower at Rs 1,323.65 apiece on the National Stock Exchange.
Meanwhile, the broader benchmark BSE Sensex was trading at 29,860.02, down 169.72 points or 0.57 per cent, at 12:05 hour.